News Feed
September 25, 2023
Northeast Node co-hosts Summit on the Intersection of Pain and Opioids
On Friday, September 29, 2023, the Northeast Node and the New England Opioid Response Network together present a regional summit: Addressing the Intersection of Pain Management and Opioid Use: Integrating Care to Promote Healthy Outcomes.
The full-day training will explore the clinical intersection of pain and opioid use, discuss the science behind both, and use an interactive approach to considering team-based integrated treatments in different settings.
For more information, including the agenda and continuing education, please visit the Summit’s website.
May 31, 2023
Teams at the Northeast Node and University of New Hampshire Citizen’s Health Initiative have published findings from a recent training program to explore the feasibility of training clinics to collect performance data and initiate Quality Improvement (QI) practice change cycles alongside clinic participation in a Project ECHO virtual collaborative for medication treatment of opioid use disorder (MOUD).
The article, published in the Journal Addiction Science & Clinical Practice, reports on the engagement of five New Hampshire primary care or mental health clinics in monitoring their own performance regarding OUD screening, buprenorphine initiation and retention, and naloxone overdose reversal device access best practices, and then using performance data to inform QI change cycles.
All five clinics met the criteria for engagement, submitted at least one month of performance data, and completed at least one QI initiative. Results suggest that training clinics to monitor their performance and base QI initiatives on clinic-derived data has the potential to impact best practice for MOUD.
Click below to read the article:
Augmenting project ECHO for opioid use disorder with data-informed quality improvement
November 8, 2022
July 20, 2022
Research Assistant Employment Opportunity
Research Assistant II
The primary purpose of this position is to implement activities for a National Institute on Drug Abuse (NIDA)-funded study investigating a prevention strategy for opioid use disorder in primary care settings. This position is based at two primary care practices in Manchester and Bedford, NH.
July 11, 2022
Faculty Employment Opportunity
Faculty Position in Application of Digital Health to The Treatment of Substance Use Disorders And/or Related Fields
The Department of Biomedical Data Science at the Geisel School of Medicine at Dartmouth (Geisel) seeks an outstanding individual to join our faculty within the Center for Technology and Behavioral Health (CTBH). CTBH is an interdisciplinary research group whose mission is to inform the optimal development, scientific evaluation, and sustainable implementation of digital therapeutics for behavioral health. CTBH is a designated “Center of Excellence” by the US National Institutes of Health (NIH).
May 25, 2022
New Overdose Data: 107,622 Overdose Deaths in 2021
Last week, the Centers for Disease Control and Prevention released provisional data showing there were 107,622 overdose deaths in 2021, the highest annual death toll on record from drug overdose fatalities, and a 15% increase from the year prior.
“We lost over 107,000 individuals to drug overdoses in 2021, 295 individuals each day. It’s time to double down our efforts to address this epidemic, including prevention, treatment, recovery services and awareness about the risks of fentanyl,” shared Jessica Hulsey, Executive Director of the Addiction Policy Forum.
According to the National Center for Health Statistics, fentanyl was involved in the most overdose deaths in 2021.
To help, you can:
1. Learn about the dangers of fentanyl.
Learn more about fentanyl from trusted sources like the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA).
2. Learn how to administer naloxone.
Learn more about how you can obtain and administer naloxone through the Naloxone Facts awareness campaign.
May 25, 2022
Funding Opportunity: Tribal Opioid Response Grants
The purpose of the TOR program is to assist in addressing the overdose crisis in Tribal communities by increasing access to FDA-approved medications for the treatment of opioid use disorder (MOUD), and supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder (OUD) and co-occurring substance use disorders. The TOR program also supports the full continuum of prevention, harm reduction, treatment and recovery support services for stimulant misuse and use disorders, including for cocaine and methamphetamine.
Eligibility is limited to federally recognized American Indian or Alaska Native Tribe or tribal organizations. Tribes and tribal organizations may apply individually, as a consortium, or in partnership with an Urban Indian Organizations.
August 30, 2021
NEW CTN STUDY: CTN-0116 PharmICO
The Northeast Node is proud to announce its newest CTN study, CTN-0116: Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder (PharmICO).
On Thursday, August 26, 2021, the CTN-0116 Lead Team hosted an Informational Session for prospective sites to learn more about the study. You can view the recording of that session below.
In addition, Site Selection material were sent to the full CTN, including a Brief Study Overview, EHR Extraction Summary, and the Site Selection Survey itself. Surveys are due back to the Lead Team no later than Friday, October 1.
Slides from this presentation are available here: CTN-0116_Site Information_2021-0826
August 30, 2021
The Northeast Node has 2 open positions for a new study based at the Dartmouth-Hitchcock Addiction Treatment Program in Lebanon, NH.
The study is a clinical trial examining the retention, duration, and discontinuation of medication treatment for opioid use disorder; it will inform the science around how long patients with OUD stay in treatment as well as how medication discontinuation occurs in real-world settings.
The study is hiring two Research Assistants (RA) to join our team here in New Hampshire. We are hoping to hire people with research experience, as this study is complex and includes an Investigational New Drug (IND) for use of the CAM2038 extended-release buprenorphine product. Employment for these two positions would occur through the College and not D-H, though shared access will be granted for D-H systems needed to conduct the study.
The RA position link is: https://searchjobs.dartmouth.edu/postings/58366
Please share this notice within your networks, and with friends and family.
December 4, 2020
The Northeast Node was awarded a new CTN study: CTN-0116
The Northeast Node was awarded a new CTN study: Pharmacist-Integrated Model of Medication Treatment for Opioid Use Disorder.